Growth hormone secretagogues

Tesamorelin

An FDA-approved GHRH analog product for a specific HIV-associated lipodystrophy indication.

Egrifta SVTH9507GHRH analog

Concise answer

What is Tesamorelin?

Tesamorelin is a GHRH analog with an FDA-approved product for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not a general fat-loss or anti-aging peptide.

Definition

What It Is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone. Unlike many peptides in wellness marketing, it has an FDA-approved prescription product for a narrow indication.

Status

Legal and Regulatory Notes

FDA: FDA-approved as Egrifta SV for a specific labeled use related to excess abdominal fat in adults with HIV-associated lipodystrophy.
Research: Randomized human trials support its labeled niche. Evidence should not be generalized to ordinary weight loss, bodybuilding, or longevity.
Sport: GHRH analogs can be anti-doping concerns. Athletes should verify official rules and therapeutic-use requirements.

Research map

How Tesamorelin Is Being Studied

HIV-associated lipodystrophy and visceral adipose tissue outcomesIGF-1 and metabolic monitoringLonger-term maintenance and rebound questionsSafety in specific patient populations

People

Human Research

Randomized human trials in people with HIV and excess abdominal fat support the labeled use. The evidence does not establish tesamorelin as a general obesity or anti-aging medication.

Models

Animal and Cell Research

Human clinical data and official labeling are more relevant for this profile than animal evidence.

Safety

Known Risks and Side Effects

Label-defined contraindications and warnings require clinician review
Potential glucose and IGF-1 monitoring considerations
Not appropriate for generalized weight-loss marketing
Athlete anti-doping and prescription compliance issues

Compliance

Interpretation Guardrails

FDA-approved status applies to the approved product and indication, not every tesamorelin-like product or use.
No dosing instructions are provided on PeptideWars.
Talk to a licensed clinician familiar with HIV metabolic care.

Internal links

Related Battles and Profiles

Profile Sermorelin A GHRH analog historically studied for growth hormone deficiency testing and pediatric growth contexts. Profile CJC-1295 An investigational long-acting GHRH analog studied for growth hormone and IGF-1 signaling. Profile Semaglutide An FDA-approved GLP-1 receptor agonist active ingredient used in prescription products for label-defined indications. Profile Tirzepatide An FDA-approved prescription active ingredient with dual GIP and GLP-1 receptor agonist activity in approved products. Guide Growth Hormone Secretagogues CJC-1295, ipamorelin, sermorelin, and tesamorelin compared by mechanism, evidence, and regulatory status. Guide Weight Management Peptides Separate FDA-approved incretin medications from research peptides and cosmetic weight-loss hype.

FAQ

Common Questions

Is tesamorelin FDA-approved?

Yes, an FDA-approved tesamorelin product exists for a specific HIV-associated lipodystrophy indication.

Is tesamorelin a general weight-loss drug?

No. Its approved use is specific and should not be generalized to ordinary weight loss or anti-aging.

How is tesamorelin different from sermorelin?

Both are GHRH analogs, but tesamorelin has an FDA-approved product for a narrow adult HIV-lipodystrophy use, while sermorelin's stronger literature is older growth hormone testing and deficiency contexts.

Sources

Citations and Official References

Editorial Review

Written by the PeptideWars Editorial Team. Medical reviewer placeholder: licensed clinician review should be completed before production launch. Last updated May 6, 2026.